Healthcare Industry News: echocardiography
News Release - October 8, 2020
First Patients Treated with Galaxy Medical's Centauri(TM) Pulsed Electric Field Cardiac Ablation SystemSAN CARLOS, Calif., Oct. 8, 2020 -- (Healthcare Sales & Marketing Network) -- Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that the first patients in the ECLIPSE-AF study were successfully treated with the proprietary Centauri™ System by Dr. Ante Anić in Split, Croatia. This multicenter trial is designed to assess the safety and efficacy of the Centauri System and is intended to support CE-Mark.
The Centauri System is uniquely designed as an open energy platform with proprietary interface hardware and waveform control algorithms, which enable electrophysiologists to continue with the established point-by-point clinical workflow used in the majority of cardiac ablation procedures worldwide. Centauri offers the enhanced safety and efficacy features of PEF energy without the typical learning curve and workflow adjustments associated with new technologies.
Key features of the Centauri System:
- Plug and play with all cardiac mapping and navigation systems
- No compromise compatibility with market-released focal and contact force sensing catheters
- Physician choice of dose setting when treating variable tissue thickness
- Proprietary technology that completely eliminates microbubbles during PEF delivery
- Automated voltage control to prevent overdosing or underdosing
PEF technology utilizes high voltage, high frequency bursts of electrosurgical energy to ablate tissue. In comparison to radiofrequency and cryoablation procedures, PEF has the potential to improve the safety of cardiac ablation by reducing the unintentional conductive heating or cooling of extracardiac structures including the esophagus, phrenic nerve, and airway. Efficacy may be enhanced with the creation of full-thickness, transmural lesions where the therapeutic dose of PEF energy is limited to the myocardium.
Jonathan Waldstreicher, MD, CEO of Galaxy Medical commented: "In developing the Centauri System, our three main priorities are safety, interoperability, and efficacy. With the complete elimination of microbubbles, which may cause cerebral or coronary air emboli, we have addressed the primary safety concern with PEF technology in the heart. On interoperability, we integrate into today's EP lab with the tools that electrophysiologists have come to depend on to deliver safe and effective patient-centered ablation procedures tailored to each patient's unique anatomy, which will lead to more rapid uptake of this technology. And on efficacy, our research has consistently demonstrated that PEF with focal catheters yields predictable and transmural lesions as opposed to inconsistent ablation depth and intermittent electrical stunning associated with multipolar catheters with variable contact. We look forward to completing enrollment of the ECLIPSE-AF study and sharing the clinical experience in the near future."
As part of the ECLIPSE-AF study, patients will be assessed and followed with extensive safety and efficacy procedures including acute demonstration of entrance and exit block, monitoring of acute ST-segment changes, assessment of microbubbles on intracardiac echocardiography, assessment of pulmonary vein anatomy, three-month electrophysiologic remapping to confirm durability of pulmonary vein isolation, Holter monitoring at long term follow-up, cerebral MRI and upper GI endoscopy.
The Centauri System is an investigational device and not approved for commercial use.
About Galaxy Medical
Galaxy Medical is a privately held medical device company based in San Carlos, CA, that is dedicated to developing therapies to treating patients with cardiac arrhythmias. Formed by Apple Tree Partners, a healthcare-focused venture capital firm based in New York, Galaxy is building a portfolio of technologies to address the needs of cardiac electrophysiologists.
Source: Galaxy Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.